Raymond James analyst David Feaster downgrades First Commonwealth (NYSE:FCF) from Outperform to Market Perform.
LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
LegoChem Biosciences, Inc. (‘LCB') (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, whereby it granted Amgen rights to research, develop, and commercialize ADCs directed against up to 5 targets selected by Amgen based on LCB's proprietary ConjuAll ADC technology.
